High Plasma levels of sTnF-r1 and ccl11 are related to cD4+ T-cells Fall in human immunodeficiency Virus elite controllers With a sustained Virologic control.
Date
2018Abstract
Our aim was to analyze the relationship between plasma inflammatory biomarkers and
CD4+ T-cells evolution in human immunodeficiency virus (HIV) elite controllers (HIVECs) with a suppressed viremia. We carried out a retrospective study in 30 HIV-ECs
classified into two groups: those showing no significant loss of CD4+ T-cells during the
observation period (stable CD4+, n = 19) and those showing a significant decrease
of CD4+ T-cells (decline CD4+, n = 11). Baseline plasma biomarkers were measured
using a multiplex immunoassay: sTNF-R1, TRAIL, sFas (APO), sFasL, TNF-α, TNF-β,
IL-8, IL-18, IL-6, IL-10, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, SDF1α, GRO-α, and
CCL11. Baseline levels of sTNF-R1 and CCL11 and sTNF-R1/TNF-α ratio correlated
with the slope of CD4+ T-cells (cells/μl/year) during follow-up [r = −0.370 (p = 0.043),
r = −0.314 (p = 0.091), and r = −0.381 (p = 0.038); respectively]. HIV-ECs with declining
CD4+ T-cells had higher baseline plasma levels of sTNF-R1 [1,500.7 (555.7; 2,060.7)
pg/ml vs. 450.8 (227.9; 1,263.9) pg/ml; p = 0.018] and CCL11 [29.8 (23.5; 54.9) vs.
19.2 (17.8; 29.9) pg/ml; p = 0.041], and sTNF-R1/TNF-α ratio [84.7 (33.2; 124.2) vs.
25.9 (16.3; 75.1); p = 0.012] than HIV-1 ECs with stable CD4+ T-cells. The area under
the receiver operating characteristic (ROC) curve [area under ROC curve (AUROC)] were
0.758 ± 0.093 (sTNF-R1), 0.727 ± 0.096 (CCL11), and 0.777 ± 0.087 (sTNF-R1/TNF-α).
The cut-off of 75th percentile (high values) for these biomarkers had 71.4% positive
predictive value and 73.9% negative predictive value for anticipating the evolution of
CD4+ T-cells. In conclusion, the loss of CD4+ T-cells in HIV-ECs was associated with
higher levels of two plasma inflammatory biomarkers (sTNF-R1 and CCL11), which were
also reasonably accurate for the prediction of the CD4+ T-cells loss.